IRCT20151227025726N13招募中2 期
Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Laboratory confirmed COVID-19 with RT-PCR
- •Respiratory rate > 30/min
- •Oxygen saturation < 90%
- •PaO2/FiO2 < 300mmHg
- •High level of serum Interleukin-6
- •Age over 18 years old
排除标准
- •Chronic kidney Disease
- •Acute kidney injury
- •Pregnancy or breastfeeding
- •Drug allergy history
- •Pneumonia due to influenza virus, bacterial pneumonia, fungal pneumonia, and noninfectious causes
- •Chronic liver disease
- •History of latent or active tuberculosis
- •Patients with human immunodeficiency virus
研究者
相似试验
已完成
不适用
Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu ArteritisTakayasu arteritisJPRN-UMIN000007845Department of Cardiovascular Medicine Graduate School of Medicine Osaka University15
招募中
不适用
The efficacy and safety of tocilizumab (trade name: Actemra) in RA patients.Rhumatoid arthritisJPRN-UMIN000002843Division of Rheumatology, Department of Internal Medicine, Kanazawa University Graduate School of Medicine20
招募中
3 期
Tocilizumab in severe COVID-19COVID-19.COVID-19U07.1IRCT20150303021315N17Aryogen Pharmed85
已完成
不适用
ong-term Safety of treatment with tocilizumab in the refractory patients with Takayasu ArteritisTakayasu arteritisJPRN-UMIN000025943Osaka Unversity9
招募中
2 期
Evaluation of the Effects of Tocilizumab Administration in Hospitalized COVID-19 PatientsIRCT20151227025726N29Iran University of Medical Sciences50